Chevy Chase Trust Holdings LLC Sells 2,160 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Chevy Chase Trust Holdings LLC decreased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 0.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 444,701 shares of the pharmaceutical company's stock after selling 2,160 shares during the quarter. Vertex Pharmaceuticals accounts for approximately 0.5% of Chevy Chase Trust Holdings LLC's investment portfolio, making the stock its 26th largest position. Chevy Chase Trust Holdings LLC owned 0.17% of Vertex Pharmaceuticals worth $179,081,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Creative Planning increased its stake in Vertex Pharmaceuticals by 1.7% in the third quarter. Creative Planning now owns 80,467 shares of the pharmaceutical company's stock valued at $37,424,000 after acquiring an additional 1,350 shares during the last quarter. NBC Securities Inc. increased its stake in shares of Vertex Pharmaceuticals by 34.5% in the 3rd quarter. NBC Securities Inc. now owns 160 shares of the pharmaceutical company's stock valued at $74,000 after purchasing an additional 41 shares during the last quarter. Wolff Wiese Magana LLC raised its holdings in shares of Vertex Pharmaceuticals by 254.5% during the 3rd quarter. Wolff Wiese Magana LLC now owns 156 shares of the pharmaceutical company's stock worth $73,000 after buying an additional 112 shares in the last quarter. Good Life Advisors LLC bought a new stake in shares of Vertex Pharmaceuticals during the 3rd quarter worth $222,000. Finally, Teamwork Financial Advisors LLC grew its position in Vertex Pharmaceuticals by 1,588.1% in the third quarter. Teamwork Financial Advisors LLC now owns 10,095 shares of the pharmaceutical company's stock valued at $4,695,000 after acquiring an additional 9,497 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Trading Up 0.7 %

Shares of VRTX stock traded up $3.11 during mid-day trading on Tuesday, hitting $462.11. The company's stock had a trading volume of 1,405,218 shares, compared to its average volume of 1,546,074. The company has a market cap of $119.01 billion, a PE ratio of -232.22, a P/E/G ratio of 1.80 and a beta of 0.41. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47. The company's fifty day simple moving average is $435.39 and its 200-day simple moving average is $460.67. Vertex Pharmaceuticals Incorporated has a 52 week low of $377.85 and a 52 week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing analysts' consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. As a group, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post -1.94 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on VRTX. Stifel Nicolaus raised their price target on shares of Vertex Pharmaceuticals from $490.00 to $494.00 and gave the company a "hold" rating in a research note on Monday, December 16th. Canaccord Genuity Group upgraded shares of Vertex Pharmaceuticals from a "sell" rating to a "hold" rating and raised their target price for the company from $408.00 to $424.00 in a research report on Tuesday, February 11th. Wells Fargo & Company downgraded shares of Vertex Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $460.00 price target for the company. in a report on Thursday, January 30th. Truist Financial raised their price objective on Vertex Pharmaceuticals from $460.00 to $520.00 and gave the company a "buy" rating in a report on Tuesday, February 11th. Finally, Citigroup started coverage on Vertex Pharmaceuticals in a report on Thursday, November 14th. They issued a "buy" rating and a $575.00 target price for the company. Ten equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $505.57.

Insider Activity

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 310 shares of Vertex Pharmaceuticals stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $459.83, for a total value of $142,547.30. Following the completion of the sale, the executive vice president now directly owns 64,021 shares of the company's stock, valued at approximately $29,438,776.43. The trade was a 0.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.20% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.